Primary Total: $52,502,661
Total: $4,982,522
Primary Total: 4,160,792
*A Multicenter, Open-Label, Study of the Safety and Tolerability of Metrifonate (BAY A 9826) in Patients with Probable Alzheimer's Disease, (428749), Miles Laboratories Inc, $57,427 (adjustment).
*A Multi-center, Open-Label Study of the Safety and Tolerability of Metrifonate (Bay A 9826) in Patients with Probable Alzheimer's Disease, (429754), Bayer Pharmaceuticals, $7,500.
Oxidant Induced Alterations in Matrix Protein Synthesis in Pulmonary Hypertension, (429230), American Heart Assoc KY Affiliate, $15,600.
*Undergraduate Research Experiences in Membrane Science, (428780), Natl Science Fdtn, $46,518 (adjustment).
*Drug Abuse Prevention -- A Lifecourse Perspective Phase III, (433328), Natl Institute on Drug Abuse, $183,119.
*Biochemical Studies of Steroid 5x- Reductase, (429440), Natl Institute Diabetes & Digestive & Kidney, $129,476.
The Effect of Head Trauma/Acute Phase Response on Brain and Liver Cytochrome P450 Enzymes, (429637), KY Cab for Human Resources, $77,299.
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433243), Natl Institute of Neurological Diseases & Stroke, $14,482 (adjustment).
*An Open-Label Study of the Pharmacokinetics of Venlafaxine in Extensive and Poor Metabolizers of Dextromethorphan, (428536), Wyeth Ayerst Research Inc, $44,972 (adjustment).
Intrapulmonary Delivery of Antibiotics in Flurocarbon Solvents, (429719), Upjohn Company, $24,734.
Annamycin - Mechanisms of Action, (429821), MD Anderson Cancer Center, $9,126.
Chemical Dynamics of Camptothecin Drugs in Human Blood, (46), American Cancer Society, $104,408.
*Immunotherapy and Gene Therapy of Cancer Program, (433366), Lucille P Markey Charitable Trust, $21,582 (adjustment).
*NSF/EPSCoR: Biofunctional Membranes: Synthesis, Structure and function, (432118), Natl Science Fdtn, $25,034 (adjustment).
Angiotensin in Brown Adipose Thermogenesis, (428879), Natl Heart Lung and Blood Institute, $124,080 (adjustment).
Angiotensin II in Brown Adipose Thermogenesis, (433444), Natl Heart Lung and Blood Institute, $35,108.
Insulin and Vascular Responsiveness, (428997), American Heart Assoc KY Affiliate, $14,907.
Angiotensin II in Brown Adipose Tissue Thermogenesis, (429181), Natl Heart Lung and Blood Institute, $68,662.
ASHP Fellowship in Geriatric Drug Therapy, (429001), American Society of Hospital Pharmacists, $27,100.
*A Double-Blind Randomized Placebo-Controlled Dose-Response Study of Inhaled Nitric Oxide (OHM-11771) in the Treatment of Acute Respiratory Distress Syndrome (ARDS), (428455), Ohmeda Pharmaceuticals, $77,082 (adjustment).
*A Double-Blind, Randomized, Placebo-Controlled Study of Inhaled Nitric Oxide in the Treatment of Acute Respiratory Disease Syndrome, (429827), Ohmeda Pharmaceuticals, $2.
Biomimetic Molecular Recognition, (429417), Natl Institute of General Medical Sciences, $64,287.
Laura Bartels ACCP Research Fellowship: Merck, Sharp & Dohme Cardiovascular Fellowship, (428986), American College of Clinical Pharmacy, $22,500.
*Onmicare Congestive Heart Failure Outcomes Study, (429843), Bristol-Myers Squibb Company, $88,843.
*A Multicenter Pharmacokinetic and Pharmacodynamic Study of Dofetilide in Subjects with Stable Atrial Fibrillation and Reduced Left Ventricular Function, (428192), Pfizer Inc, $42,977 (adjustment).
*Mechanisms of Interstitial Pneumonitis in Murine AIDS, (428218), Natl Heart Lung and Blood Institute, $227,685 (adjustment).
Delivery of LHRH Analogue Using a Biodegradable Microsphere, (427522), Ben Venue Laboratories Inc, $169,622 (adjustment).
*Interaction of Peptides with Hydrophobic Biodegradable Polymers, (427625), Debio Recherche Pharmaceutique, $30,870 (adjustment).
Synthesis of Prodrugs for Opthalmic Delivery, (426853), Control Delivery Systems Inc, $124,220 (adjustment).
A Novel Hormone Delivery System for Treating Osteopenia, (429592), Univ of Florida, $80,000.
In Vivo Scintigraphic Evaluation of a Pulsatile Delivery System (PORT), (429453), Therapeutic Systems Research Laboratories, $22,025.
An Evaluation of Nasal Spray Deposition and Clearance Part III: Desmopressin Acetate Nasal Solutions, (429557), Bausch and Lomb, $9,362.
Development and Testing of Guar Gum Formulations, (427809), CIBUS Pharmaceutical Inc, $46,860 (adjustment).
In Vivo Evaluation of the Absorption and GI Transit of BMS-180048 in the Fed and Fasted Subjects Using Gamma Scintigraphy, (429560), Bristol Myers, $37,953.
An Evaluation of Nasal Spray Deposition and Clearance Part II: Flunisolide Nasal Solutions, (429494), Bausch and Lomb, $9,362.
External Scintigraphy and Pharmacokinetic Studies on Oral Formulations of Drugs Which Show Discontinuous Absorption in the Gastrointestinal Tract, (429426), Recordati, $26,057.
In Vitro Diffusion of Iodine from Duraprep, (429257), 3M Co, $9,765.
A Pharmacokinetic and Scintographic Evaluation of Ramitidine Guar Gum Formulations in Healthy Human Volunteers, (428753), CIBUS Pharmaceutical Inc, $15,348 (adjustment).
F-19 (NMR) Analysis of Trifluorocetic Acid (TFA) in Human Urine Samples, (429405), 3M Co, $10,958.
An Evaluation of Nasal Spray Deposition and Clearance, (429308), Bausch and Lomb, $12,512.
Gamma Scintigraphic Determination in Beagles of In Vivo Disintegration and Dispersal of Oral Dosage Forms Containing Bile Salt Sequestering Agents, (429673), DuPont Merck Pharmaceutical Company, $40,320.
Pilot Synthesis of 2'-MPA, (429692), Baker Norton Pharmaceuticals, $55,440.
Fellowship for Katheryne Webb: Pursuit of Neuronal Nicotinic Antagonists: Potential Treatment for Nicotine Addiction, (429207), American Assoc of Colleges of Pharmacy, $7,000.
Drug Abuse Prevention -- A Lifecourse Perspective Phase III, (433357), Natl Institute on Drug Abuse, $40,276.
Cloning of the cDNA for 15 Ketoprostaglandin 13 Reductase, (429081), American Lung Assoc, $24,838.
Cloning and Deletion Analysis of the Promoter Region of the Thrombodxane A2 Receptor Gene, (429229), American Heart Assoc KY Affiliate, $13,795.
Bioequivalence Guidelines, (429858), United States Pharmacopeial Convention, $10,000.
Living with GERD Outcome Study, (429820), Eli Lilly and Co, $5,000.
Polyamine Dependence of Hypertensive Vascular Changes, (429723), Natl Heart Lung and Blood Institute, $213,152.
Application of Photoaffinity Labeling, (429079), Ephraim McDowell Cancer Research Fdtn, $25,000.
AREA: DNA-Binding Proteins in the Obese Zucker (fa/fa) Rat, (429366), Natl Institute Diabetes & Digestive & Kidney, $93,174.
Development of Gene Therapy for Hypoxic-Induced Pulmonary Hypertension, (428999), American Heart Assoc KY Affiliate, $18,000.
Hyperlipidemia Initiative - War on Coronary Heart Disease, (429507), Multiple Industry Sponsors, $86,170.
Kentucky Medicaid Contract - Boards Management Part III, (433318), KY Cab for Human Resources, $35,633.
Kentucky Medicaid Contract - Education Program-Part II, (433309), KY Cab for Human Resources, $80,240.
Kentucky Medicaid Contract, (429492), KY Cab for Human Resources, $228,432.
Alteration of NAD Metabolism by Chemical Carcinogens, (429054), Natl Cancer Institute, $172,424.
Measurement of Gastrointestinal Transit of Compound A by Gamma Scintigraphy, (429813), Scintiprox Inc, $7,907.
Pharingeal Retention of Viscous Formulations, (429506), Procter & Gamble Company, $50,670.
*Short Title: Nebulizer Systems Study for Mild Cystic Fibrosis, (428889), Genentech Inc, $16,799 (adjustment).
*An Active Treatment Study of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metHuBDNF) Given by Daily Subcutaneous Injections to Patients with Amyotrophic Lateral Sclerosis (ALS), (460093), AMGen, $2.
*A Trial of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-met HuBDNF) Given by Daily Subcutaneous Injections to Patients in Amyotrophic Lateral Sclerosis (ALS), (427975), AMGen, $217,375 (adjustment).
*A Trial of Recombinant Methionyl Human Brain-Derived Neurotropic Factor (r-met BDNF) Given by Daily Subcutaneous Injection to Patients with Amyotrophic Lateral Sclerosis Part C, (433350), AMGen, $131,129.
*An Open Labl Safety Study of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metBDNF) Given by Daily Subcutaneous Injection to Patients with Amytrophic Lateral Sclerosis, (428847), AMGen, $19,799 (adjustment).
*Evaluation of the Role for Multidrug Resistance (MDR) Genes in Normal Human Lymphocyte Function, (428775), Pharmaceutical Manufacturers Assoc Fdtn, $12,500 (adjustment).
*A Trial to Evaluate the Efficacy and Safety of Two Doses of Lexipafant for the Treatment of Acute Pancreatitis, (429908), British Biotech Inc, $2.
*Randomized, Placebo-Controlled Trial of MAK 195F in Sepais with Hyperinflammatory Response, (429751), Knoll Pharmaceutical Company, $11,001.
Mental Health Research and Data Management, (429042), Dept for Mental Health/Mental Retardation Services, $543,990.
Input of Continous Pharmaceutical Care on Outcomes in Chronically Ill Patients, (429045), Dept for Mental Health/Mental Retardation Services, $77,750.
An Open-Label Assessment of the Long-Term Safety of Sertindole in Schizophrenic Patients, (429531), Abbott Laboratories, $1.
*A Double-Blind Comparison of Sertindole and Haldol: An Assessment of the Chronic Safety, Efficacy, Quality of Life and Relapse in Stable Schizophrenic Patients, (428031), Abbott Laboratories, $37,143 (adjustment).
*A Randomized Trial to Assess the Outcomes and Costs of Risperdal versus Conventional Antipsychotic Therapy in Patients with Chronic Schizophrenia, (429319), Janssen Research Fdtn, $1,000 (adjustment).
*Dose Response Study in the Treatment of Negative symptoms of Schizophrenia with Pramipexole, (429315), Upjohn Company, $11,480.
The Analgesic Effects of Tricyclic vs Serotonin Specific Reuptake Inhibitor Antidepressant in Low Back Pain, (428017), Pain Care Inc, $5,454 (adjustment).
*Passive Smoking During Pregnancy: Cognitive Development, (427649), Natl Institute of Environmental Health Sciences, $105,974 (adjustment).
*Development Neurotoxicity of Cocaine: An IV Rat Model, (428298), Natl Institute on Drug Abuse, $197,938 (adjustment).
Development and Manufacture of DHEA Capsules and Matching Placebos by the Pharmaceutical Technology Unit for Neurocrine Biosciences, (429563), Neurocrine Biosciences Inc, $70,008.
Preparation of EDLA, (429720), Maxell Limited, $102,226.
Preparation of Dual Label PORT, Coated Hard Gelatin Capsules, (429452), Therapeutic Systems Research Laboratories, $9,204.
Preparation of a Sterile Dosage Form of OKT3-gamma, ALA/ALA, (429282), Univ of Chicago, $5,000 (adjustment).
Preparation of a Bradykinin Parenteral Dosage Form by the Pharmaceutical Technology Unit, (429871), Univ of Louisville, $10,093.
Effects of Prenatal Nicotine Exposure on Brain nAChr, (429822), Natl Institute on Drug Abuse, $57,513.
Effects of Prenatal Nicotine Exposure on Brain nAChr, (433434), Natl Institute on Drug Abuse, $5,622.
*Double-Blind, Randomized, Placebo-Controlled, Parallel- Group Trial of the Efficacy of Enlimomab (Anti-ICAM-1) Compared to Placebo Administered Within 6 hours of the Onset of Stroke Symptoms of Treatment of Acute Ischemic Stroke, (428573), Boehringer Ingelheim, $121,769 (adjustment).
*A Placebo-Controlled Study to Determine the Effects of 500mg, 1000mg, and 2000mg Citicoline in Ischemic Stroke Patients, (428018), Parexel International Co, $51,167 (adjustment).
*A Phase I/II, Open-Label, Rising-Dose, Safety and Feasibility Study of SNX-111 Administered Intrathecally to Terminally Ill Patients Suffering from Chronic Pain, (428718), Neurex, $30,085 (adjustment).
AMES Mutagenicity Testing with Recombinant Human P450s, (428823), Natl Institute of Environmental Health Sciences, $109,604 (adjustment).
Medication Use Evaluation Study of High Dose Urokinase in Arterial Occlusion, (429555), Abbott Laboratories, $8,291.
Impact of Continous Pharmaceutical Care on Outcomes in Chronically Mentally Ill, (429317), American Society of Hospital Pharmacists, $6,000.
*Comparison of the Safety, Efficacy and Economic Impact of Sequential (IV to PO) Ciprofloxacin Plus Metronidazole with Piperacillin/Tazobactam for the Treatment of Patients with Complicated Intraabdominal Infection, (429983), Bayer Pharmaceuticals, $2.
Angiotensin and the Vascular ODC/Polyamine System in Hypertension, (428998), American Heart Assoc KY Affiliate, $16,490.
*A Trial to Determine the Safety and Efficacy of Affinity Purified Digoxin Fab (Ovine, Lyophilized) Tab007-01, (429870), Therapeutic Antibodies, $3,000.
*Effects of Myocardial Ischemia on B-Receptor Subtype Numbers and Electrophysiologic Response to B2 Receptor Stimulation, (429102), American Heart Assoc KY Affiliate, $18,000.
Role of Gastrointestinal Microflora on Selegiline N- Dealkylation, (429490), Somerset Pharmaceuticals, $6,423.
*The Mechanisms of Warfarin Resistance, (429228), American Heart Assoc KY Affiliate, $14,294.
*A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Metrifonate (BAY A 9826) in Patients with Probable Alzheimer's Disease D95-018, (429559), Bayer Pharmaceuticals, $114,684.
*Safety and Efficacy of Tiagabine HCL Monotherapy in the Treatment for Partial Seizures: High Dose Versus Low Dose, (427742), Abbott Laboratories, $6,480 (adjustment).
Microbiologic Assessment of Filters as Bacterial Retentive, (428783), Imed Co, $4,337 (adjustment).
*An Open Study to Investigate the Biliary Excretion of L-748, 731 and its Metabolites Following Single Oral Doses of C-L-748, 731 in Patients Having a Surgically Implanted T-Tube, (429693), Merck and Company Inc, $2.
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6/30/03